Radiopharm Theranostics Limited (AU:RAD) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Radiopharm Theranostics has received ethics approval in Australia to initiate a Phase 1 clinical trial of their innovative cancer treatment, 177Lu-RAD202, targeting HER2-positive metastatic solid tumors. This trial aims to explore the safety and clinical activity of the treatment, offering a potential new strategy for patients resistant to current therapies. The study underscores Radiopharm’s commitment to addressing unmet medical needs in oncology.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.